Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Rating) has earned a consensus rating of “Buy” from the fifteen ratings firms that are presently covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $29.00.
Several research firms have recently weighed in on ALLO. The Goldman Sachs Group decreased their price target on shares of Allogene Therapeutics from $20.00 to $12.00 and set a “neutral” rating on the stock in a research note on Monday, March 7th. JMP Securities reaffirmed a “buy” rating and set a $23.00 target price on shares of Allogene Therapeutics in a research note on Monday, April 11th. HC Wainwright reiterated a “buy” rating and set a $43.00 price target on shares of Allogene Therapeutics in a research report on Friday, March 4th. William Blair reiterated an “outperform” rating on shares of Allogene Therapeutics in a research report on Tuesday, March 29th. Finally, B. Riley dropped their price target on shares of Allogene Therapeutics from $30.00 to $21.00 and set a “buy” rating for the company in a research report on Monday, February 28th.
NASDAQ:ALLO opened at $6.97 on Friday. The company’s 50-day moving average price is $8.73 and its 200-day moving average price is $12.49. The company has a market cap of $1.00 billion, a P/E ratio of -3.17 and a beta of 0.88. Allogene Therapeutics has a twelve month low of $6.43 and a twelve month high of $31.77.
Allogene Therapeutics (NASDAQ:ALLO – Get Rating) last posted its quarterly earnings results on Wednesday, May 4th. The company reported ($0.56) earnings per share for the quarter, topping the consensus estimate of ($0.58) by $0.02. Allogene Therapeutics had a negative net margin of 148,214.64% and a negative return on equity of 32.28%. During the same period in the prior year, the company earned ($0.25) EPS. As a group, analysts expect that Allogene Therapeutics will post -2.59 earnings per share for the current year.
In other Allogene Therapeutics news, CEO David D. Chang sold 23,648 shares of the business’s stock in a transaction that occurred on Tuesday, March 15th. The shares were sold at an average price of $7.65, for a total transaction of $180,907.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Eric Thomas Schmidt sold 11,469 shares of the business’s stock in a transaction that occurred on Tuesday, March 15th. The stock was sold at an average price of $7.63, for a total transaction of $87,508.47. The disclosure for this sale can be found here. Insiders sold 57,833 shares of company stock valued at $442,595 in the last 90 days. Company insiders own 26.30% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Allspring Global Investments Holdings LLC purchased a new stake in shares of Allogene Therapeutics during the 4th quarter worth approximately $38,000. Point72 Hong Kong Ltd purchased a new stake in shares of Allogene Therapeutics during the 4th quarter worth approximately $63,000. InterOcean Capital Group LLC purchased a new stake in shares of Allogene Therapeutics during the 1st quarter worth approximately $109,000. Virginia Retirement Systems ET AL purchased a new stake in shares of Allogene Therapeutics during the 1st quarter worth approximately $113,000. Finally, Victory Capital Management Inc. lifted its position in shares of Allogene Therapeutics by 13.3% during the 1st quarter. Victory Capital Management Inc. now owns 14,335 shares of the company’s stock worth $120,000 after buying an additional 1,688 shares during the last quarter. Institutional investors own 75.33% of the company’s stock.
About Allogene Therapeutics (Get Rating)
Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL.
Receive News & Ratings for Allogene Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Allogene Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.